Dudley Capital Management LLC Boosts Stock Position in Johnson & Johnson $JNJ

Dudley Capital Management LLC lifted its holdings in Johnson & Johnson (NYSE:JNJ) by 0.2% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 45,342 shares of the company’s stock after purchasing an additional 68 shares during the period. Johnson & Johnson accounts for approximately 3.5% of Dudley Capital Management LLC’s portfolio, making the stock its 5th biggest holding. Dudley Capital Management LLC’s holdings in Johnson & Johnson were worth $6,926,000 at the end of the most recent quarter.

Other institutional investors have also made changes to their positions in the company. GFG Capital LLC bought a new stake in shares of Johnson & Johnson in the 2nd quarter worth approximately $35,000. Stone House Investment Management LLC bought a new stake in shares of Johnson & Johnson in the 1st quarter worth approximately $47,000. 1248 Management LLC bought a new stake in shares of Johnson & Johnson in the 1st quarter worth approximately $48,000. von Borstel & Associates Inc. bought a new stake in shares of Johnson & Johnson in the 1st quarter worth approximately $49,000. Finally, Harvest Fund Management Co. Ltd bought a new stake in shares of Johnson & Johnson in the 1st quarter worth approximately $52,000. 69.55% of the stock is currently owned by institutional investors.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the company’s stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the transaction, the executive vice president owned 178,013 shares of the company’s stock, valued at approximately $31,652,491.53. This represents a 24.08% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson Stock Performance

Johnson & Johnson stock opened at $192.81 on Thursday. The stock has a 50-day simple moving average of $181.64 and a 200 day simple moving average of $165.56. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $194.48. The company has a quick ratio of 0.76, a current ratio of 1.01 and a debt-to-equity ratio of 0.50. The stock has a market capitalization of $464.35 billion, a price-to-earnings ratio of 18.61, a P/E/G ratio of 2.25 and a beta of 0.40.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. Johnson & Johnson had a return on equity of 33.08% and a net margin of 27.26%.The firm had revenue of $24.02 billion for the quarter. On average, research analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 9th. Shareholders of record on Tuesday, November 25th will be issued a dividend of $1.30 per share. The ex-dividend date of this dividend is Tuesday, November 25th. This represents a $5.20 annualized dividend and a yield of 2.7%. Johnson & Johnson’s dividend payout ratio is currently 50.19%.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on JNJ shares. Erste Group Bank upgraded Johnson & Johnson from a “hold” rating to a “buy” rating in a research note on Wednesday, July 23rd. Daiwa Capital Markets upgraded Johnson & Johnson from a “neutral” rating to an “outperform” rating and set a $203.00 price objective on the stock in a research note on Monday. Argus set a $210.00 price objective on Johnson & Johnson in a research note on Wednesday, October 15th. Piper Sandler restated an “overweight” rating on shares of Johnson & Johnson in a research report on Thursday, July 17th. Finally, Loop Capital set a $190.00 price target on Johnson & Johnson in a research report on Wednesday. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $199.05.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.